Skip to main content
Dominik Paul Modest on Muck Rack

Dominik Paul Modest

As seen in: Nature, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dominik Paul

Contact Dominik Paul, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Acute ischemic stroke, active malignancy and non-bacterial thrombotic endocarditis: an exploratory prospective observational study

|
By Athanasios Frydas, Hong Ran, Kudrat Rakhimov, Wolfram Doehner, Frank Tacke, Dominik Paul Modest, Anne Flörcken, Ingo Hilgendorf, Daniel Morris, Eberhard Siebert, Christoph Leithner, Ela Marie Akay, Sarah Ouldali, Mazen Merhi, Frieder Pfäfflin, Linda Jürgens, Maximilian Schoels, Matthias Schneider-Reigbert
| Nature Verified
Abstract About 3–10% of patients with acute ischemic stroke (AIS) have active cancer. Malignancy-associated hypercoagulability (MAH) is an established cause of cancer-associated stroke. Nonbacterial thrombotic endocarditis (NBTE) is a severe manifestation of MAH. However, no prospective study has examined its prevalence and anticoagulation management in AIS.
Open in Who Shared Issue with article?

Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer | Journal of Clinical Oncology

|
By Dominik Paul Modest, Sebastian Stintzing, Beatrice Borelli
| brnw.ch
Data Supplement Authors retain all rights in any data supplements associated with their articles The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned.
Open in Who Shared Issue with article?

Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial

|
By Dominik Paul Modest, Lisa Salvatore, David Páez López-Bravo, Julien Taieb
| The Lancet Verified
Introduction Colorectal cancer is one of the leading causes of death from cancer worldwide, with metastases being the major cause of colorectal cancer-related mortality; the 5-year survival rate for metastatic colorectal cancer is approximately 15%.1,2 In addition to poor survival, the disease burden and toxicity associated with treatment can have a substantial effect on patients' health-related quality of life (HRQoL) with impairments reported for various HRQoL aspects such as fatigue, pain,...
Open in Who Shared Issue with article?
See all 10 articles